Co-Authors
This is a "connection" page, showing publications co-authored by Marina Chiara Garassino and James Dolezal.
Connection Strength
0.905
-
What is the ideal endpoint in early-stage immunotherapy neoadjuvant trials in lung cancer? Ther Adv Med Oncol. 2023; 15:17588359231198446.
Score: 0.230
-
Deep learning generates synthetic cancer histology for explainability and education. NPJ Precis Oncol. 2023 May 29; 7(1):49.
Score: 0.225
-
Uncertainty-informed deep learning models enable high-confidence predictions for digital histopathology. Nat Commun. 2022 11 02; 13(1):6572.
Score: 0.217
-
Developing a low-cost, open-source, locally manufactured workstation and computational pipeline for automated histopathology evaluation using deep learning. EBioMedicine. 2024 Sep; 107:105276.
Score: 0.061
-
Evaluation of Major Pathologic Response and Pathologic Complete Response as Surrogate End Points for Survival in Randomized Controlled Trials of Neoadjuvant Immune Checkpoint Blockade in Resectable in NSCLC. J Thorac Oncol. 2024 Jul; 19(7):1108-1116.
Score: 0.059
-
PEOPLE (NTC03447678), a phase II trial to test pembrolizumab as first-line treatment in patients with advanced NSCLC with PD-L1 <50%: a multiomics analysis. J Immunother Cancer. 2023 06; 11(6).
Score: 0.056
-
The EU-funded I3LUNG Project: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy. Clin Lung Cancer. 2023 06; 24(4):381-387.
Score: 0.055